金融界2025年4月26日消息，国家知识产权局信息显示，松下新能源(无锡)有限公司取得一项名为"电池 充电机构"的专利，授权公告号 CN 222785789 U，申请日期为2024年6月 专利摘要显示， 本实用新型提供一种适合对多个电池同时进行预充电的电池充电机构， 具备治具(1)，其 中设置有多个电池槽(11)，可容纳多个电池(5);充电组件(2)，至少具备针板(23)，多个针状的充电端子 (21)固定在所述针板(23)上;气缸(3)，位于所述充电组件(2)的上方;以及底板(4)，具备2条以上的定位挡板 (42，44)，其特征在于，所述治具(1)通过所述定位挡板(42，44)被定位于所述底板(4)的表面，在所述气 缸(3)的驱动下，所述充电组件(2)可相对于所述治具(1)向下方移动，从而通过所述充电端子(21)对所述电 池(5)进行充电。 关注公众号，点击公众号主页右上角" ··· "，设置星标 "⭐" ，关注 鑫椤锂电 资讯~ 本文来源：当升科技 天眼查资料显示， 松下新能源(无锡)有限公司， 成立于2001年，位于无锡市，是一家以从事电气机械和 器材制造业为主的企业。企业注册资本600000万日元。通过 ...

金融界 2025 年 4 月 30 日消息，国家知识产权局信息显示，中国石油化工股份有限公司;中石化（大 连）石油化工研究院有限公司申请一项名为"渣油加氢产物收率确定方法、装置、电子设备及存储介 质"的专利，公开号 CN119886847A，申请日期为 2023 年 10 月。 专利摘要显示，本发明提供一种渣油加氢产物收率确定方法、装置、电子设备及存储介质，所述方法包 括：获取进料信息，其中，所述进料信息至少包括进料硫含量、进料残碳含量、进料镍含量、进料钒含 量、进料温度以及进料压力；将所述进料信息输入至预训练后的自编码器模型，得到所述自编码器模型 输出的多个渣油加氢产物的多个初始收率，其中，所述渣油加氢产物与所述进料信息相对应；基于各所 述渣油加氢产物的初始收率，得到各所述渣油加氢产物的目标收率。实现了能够准确、客观确定各渣油 加氢产物的目标收率。 天眼查资料显示，中国石油化工股份有限公司，成立于2000年，位于北京市，是一家以从事石油、煤炭 及其他燃料加工业为主的企业。企业注册资本12173968.9893万人民币。通过天眼查大数据分析，中国 石油化工股份有限公司共对外投资了256家企业，参与招投标项目5 ...

金融界2025年4月30日消息，国家知识产权局信息显示，江苏力星通用钢球股份有限公司、江苏星业精 密滚子科技有限公司申请一项名为"一种降低滚子端跳的工艺"的专利，公开号CN119876572A，申请日 期为2024年12月。 专利摘要显示，本发明公开了一种降低滚子端跳的工艺，步骤一：将已经完成车削待热处理的滚子放入 450‑500℃的炉子中，保温40‑60分钟后出炉空冷；步骤二：将完成空冷后的待热处理滚子完成热处理后 进行应力测试；步骤三，经过这种工艺热处理后的圆锥滚子，滚子表面应力由原来的拉应力，变成了压 应力；滚子端跳明细得到改善，有的滚子端跳甚至没有变化。优点是通过加热机构对滚子进行高温热处 理，这样先对滚子进行温度较低的热处理，可以使滚子在进行高温热处理时减少端跳的发生。 天眼查资料显示，江苏力星通用钢球股份有限公司，成立于2000年，位于南通市，是一家以从事通用设 备制造业为主的企业。企业注册资本29403.0484万人民币。通过天眼查大数据分析，江苏力星通用钢球 股份有限公司共对外投资了12家企业，参与招投标项目16次，财产线索方面有商标信息10条，专利信息 282条，此外企业还拥有行政许可15个 ...

Core Viewpoint - After years of patent disputes, leading companies in the panel (semiconductor display) industry, BOE and Samsung, may be approaching a reconciliation due to narrowing differences over advertising fees and potential collaboration opportunities in the LCD market [2][6][7]. Group 1: Patent Disputes and Market Dynamics - The patent litigation between Samsung and BOE has been ongoing for several years, with a notable deterioration in their relationship since 2022, primarily due to disputes over advertising fees and patent infringements [3][4]. - In 2021, BOE ranked second in the LCD market for Samsung's television screens, but the relationship soured in 2022 when BOE refused to pay the advertising fees demanded by Samsung, leading to a significant reduction in BOE's supply of LCD screens to Samsung [3][4]. - As of April 2023, Samsung Display initiated a new lawsuit against BOE in the U.S., marking the third legal action against BOE in two years, while BOE has also counter-sued Samsung for patent infringement [3][4]. Group 2: Competitive Landscape and Technological Advancements - The competition between BOE and Samsung in the OLED sector has intensified, with BOE's rapid development posing a significant challenge to Samsung's dominance in the OLED market [4][5]. - As of 2023, Samsung holds nearly 30,000 OLED-related patents, while BOE closely follows with approximately 28,000 patents, indicating a narrowing gap in technological capabilities [4][5]. - BOE has surpassed LG Display in the automotive OLED shipment volume and has successfully entered the supply chains of major smartphone manufacturers like Xiaomi, Huawei, and Apple [5]. Group 3: Potential Reconciliation and Future Collaboration - With major Korean panel manufacturers exiting the LCD market, Samsung and LG may become key customers for BOE's LCD products, prompting discussions of potential reconciliation [6][7]. - Samsung's strategy includes diversifying its LCD supply chain and improving its business relations in China, making reconciliation with BOE a priority [6][7]. - The upcoming discussions between BOE and Samsung are expected to address not only patent fee negotiations but also how to manage marketing costs associated with television sales, which could lead to a more collaborative relationship [6][7].

Group 1 - The core viewpoint of the news is the milestone significance of the first joint meeting of the Shantou, Chaozhou, and Jieyang cities, which aims to promote high-quality development in the Shantou-Chaozhou-Jieyang urban agglomeration through a comprehensive action plan for 2025-2026 [1][2] - The action plan establishes a top-level design for the urban agglomeration, including a rotating chair system for joint meetings and a leadership group composed of city leaders to enhance collaboration across various sectors [1][2] - The meeting marks a transition from "coordinated development" to "integrated construction," emphasizing the need for a more cohesive economic and infrastructural framework among the three cities [1][2] Group 2 - The action plan outlines four key areas of cooperation, with a total of 22 specific tasks and 29 priority projects for the current year, focusing on enhancing regional economic vitality [2][3] - A comprehensive transportation system is prioritized, aiming to establish a "one horizontal, four vertical, three ring" transportation framework to facilitate connectivity and economic integration [3] - The plan addresses the high degree of industrial homogeneity among the three cities by promoting the upgrading of traditional industries and the clustering of digital industries, thereby creating a modern industrial system that is collaborative and complementary [3]

Core Viewpoint - The company reported a net profit loss of approximately 724.52 million yuan for the year 2024, with no cash dividends or stock bonuses proposed for shareholders [33][87]. Company Overview - The company specializes in the research, production, and sales of patented innovative traditional Chinese medicine, while also expanding into biopharmaceuticals and the health industry [4][5]. - The company has developed a unique research model for innovative traditional Chinese medicine, focusing on major diseases and leveraging its strong scientific research capabilities [5][6]. Business Segments Traditional Chinese Medicine - The company holds 17 patented traditional Chinese medicines, covering eight major clinical disease systems, with leading positions in cardiovascular and respiratory disease treatments [5][19]. - Key products include Tongxinluo capsules, which treat coronary heart disease and cerebral infarction, and have received multiple national science and technology awards [8]. Biopharmaceuticals - The company has established a comprehensive development strategy for biopharmaceuticals, including international registration and global sales [6]. - It has received approvals for 13 ANDA products in the U.S. market and has submitted registration applications in 53 countries [6][20]. Health Industry - The company is actively developing health products based on traditional Chinese health theories, integrating modern technology [7]. - It has launched a series of health products aimed at various health needs, including heart health and anti-aging [7]. Financial Performance - The company achieved a total revenue of approximately 6.51 billion yuan in 2024, with a significant net loss [33]. - The proposed profit distribution plan for 2024 includes no cash dividends or stock bonuses, reflecting the company's current financial situation [87]. Market Position - The company ranks 7th among traditional Chinese medicine companies in China and 30th in the broader pharmaceutical industry [17]. - Despite a declining trend in the market for traditional Chinese medicine for cardiovascular diseases, the company has maintained a growing market share in oral formulations [19]. Product Performance - The market share of key products such as Tongxinluo capsules has increased from 13.64% in 2015 to 17.69% in the first half of 2024 [19]. - The company’s diabetes medication, Jinlida granules, saw its market share rise from 4.42% in 2015 to 16.20% in the first half of 2024 [20].

Core Insights - The Chinese pharmaceutical industry has made significant advancements in innovative drug development over the past decade, driven by supportive policies and reforms [1] - Currently, domestic pharmaceutical companies are reassessing strategies and exploring new business models due to challenges such as declining drug prices, financing difficulties, and geopolitical risks [1] - Global pharmaceutical giants are experiencing a performance divide, with companies like Merck, AstraZeneca, and Novartis showing resilience through innovative products, while others like Bristol-Myers Squibb and Roche face short-term challenges due to declining revenues from mature products [1][4] Industry Trends - The first quarter of 2025 is referred to as the "patent cliff year," where major drugs face generic competition, prompting companies to adopt diversification strategies to mitigate impacts [2][5] - Innovation in oncology, autoimmune, and neurological disease sectors remains crucial for growth, with companies needing to maintain rapid innovation and flexible localization strategies [2] - The global pharmaceutical market is projected to grow significantly, with spending expected to reach approximately $2.2 trillion by 2028, driven by increased drug usage, new product launches, and the rise of biosimilars [12] Company Performance - Bristol-Myers Squibb reported total revenue of $11.2 billion in Q1 2025, a 6% decline year-over-year, with growth products contributing $5.6 billion, while mature products saw a 20% revenue drop [4] - Roche's total revenue for Q1 2025 was approximately $18.5 billion, with a 6% year-over-year increase, driven by strong sales of innovative drugs, although the Chinese market faced a 23% decline [6][7] - Johnson & Johnson's Q1 2025 revenue reached $21.89 billion, a 2.4% increase, with significant contributions from CAR-T therapy Carvykti, which saw a 135% increase in sales [8] Strategic Adjustments - Companies are increasingly focusing on innovation and strategic partnerships to navigate market challenges, with many adopting dual strategies that combine internal R&D with external collaborations [15][16] - The need for cost control and operational optimization is evident, as companies like Roche and Bristol-Myers Squibb implement restructuring measures to adapt to market pressures [7][4] - The pharmaceutical industry is witnessing a shift towards differentiated value propositions and breakthrough innovations, with companies leveraging acquisitions and partnerships to enhance their market positions [11][15]

Group 1 - Guangdong Province's Market Supervision Administration has issued the "Notice on the 2025 Guangdong Patent Transformation and Application Initiatives," focusing on promoting patent industrialization and enhancing the real economy [1] - The initiative includes 28 specific measures aimed at accelerating the transformation of innovative achievements into productive forces [1] - By 2025, the goal is to increase the patent industrialization rate of universities and research institutions in the province by over 20% [1] Group 2 - Guangdong aims to improve the effectiveness of patent transformation and application by establishing a regular mechanism for technology demand release [2] - The province plans to achieve 170,000 patent transfers (including assignments) and over 55,000 licensing (including being licensed) by 2025 [2] - There will be a focus on promoting patent-intensive products, with a target of reaching over 15,000 patent product registrations by 2025 [2]

Group 1 - The core viewpoint of the news is that Semiconductor Manufacturing International Corporation (SMIC) has obtained a patent for a "fixture component" that enhances the precision of wafer handling and placement [1][3] Group 2 - SMIC Tianjin was established in 2003, located in Tianjin, with a registered capital of 129 million USD, and has participated in 104 bidding projects and holds 384 patents [2] - SMIC Shanghai was established in 2000, located in Shanghai, with a registered capital of 244 million USD, has invested in 4 companies, participated in 117 bidding projects, and holds 5000 patents [2]

专利摘要显示，本发明公开了一种螺旋槽式的电气线缆贯穿件及其制造方法，涉及电气线缆贯穿件结构 领域，包括承压连接壳，承压连接壳的两端分别是高压端和低压端；承压连接壳上存在贯穿通孔贯穿高 压端和低压端，且贯穿通孔内靠近低压端的位置处设置有限位部；在贯穿通孔内，设置有芯体，芯体的 外周上具有至少一条螺旋形的螺旋槽，每个螺旋槽内布设有电气线缆，且存在粘合剂填充所有螺旋槽； 芯体的外壁与贯穿通孔的内壁之间存在粘合剂填充；芯体的一端通过底部支撑塞与限位部连接，高压端 连接有压紧机构并且压紧机构作用于芯体的另一端；电气线缆的两端分别穿过底部支撑塞和压紧机构。 本发明能够在高压力差的环境下起到良好的密封效果。 天眼查资料显示，四川科新机电股份有限公司，成立于1997年，位于德阳市，是一家以从事专用设备制 造业为主的企业。企业注册资本27392.3271万人民币。通过天眼查大数据分析，四川科新机电股份有限 公司共对外投资了6家企业，参与招投标项目739次，财产线索方面有商标信息2条，专利信息88条，此 外企业还拥有行政许可119个。 金融界 2025 年 4 月 28 日消息，国家知识产权局信息显示，四川科新机电股份有限公司申 ...